This document is a publication of a European patent application (EP4711465A2) by Fred Hutchinson Cancer Center. It details "compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers," specifically focusing on a technique for transient nucleic acid expression to achieve permanent therapeutic changes in cells, referred to as "hit and run" effects. The patent application is classified under IPC C12N 15/62 and is designated for multiple European states.

As this is a patent publication, it does not impose direct compliance obligations on regulated entities. However, it represents a development in the field of cell therapy and gene editing technologies. Companies involved in biotechnology, pharmaceutical research, and cell therapy development should be aware of this patent's claims as it may impact future research, development, and commercialization strategies in this area. No specific compliance deadlines or actions are mandated by this publication.